Dengue Vaccination Recommendations
For children and adolescents aged 9-16 years living in dengue-endemic areas of the United States (Puerto Rico, American Samoa, U.S. Virgin Islands, and associated territories), dengue vaccination with Dengvaxia is recommended ONLY if they have laboratory-confirmed evidence of previous dengue infection 1.
Vaccine Choice and Availability
Dengvaxia (CYD-TDV)
- Currently the only dengue vaccine licensed in the United States 1
- Live-attenuated, chimeric tetravalent vaccine built on yellow fever 17D backbone
- Critical safety concern: Increases risk of severe dengue in dengue-naïve individuals who experience their first natural infection after vaccination 1
- Production discontinued in 2024 due to low demand 2
Qdenga (TAK-003)
- Licensed in Europe and other regions but NOT currently approved in the United States 3
- Shows 80% overall vaccine efficacy at 12 months 4
- Important limitation: Does not provide protective effect against DENV-3 in dengue-naïve individuals 4
- Recent data shows efficacy varies by age: 43.5% in 4-5 year-olds, 63.5% in 6-11 year-olds, and 67.7% in 12-16 year-olds for virologically confirmed dengue 5
Age Eligibility
Ages 9-16 years only for Dengvaxia in the United States 1, 6
The 2025 ACIP schedule clarifies that vaccination is recommended for "certain high-risk groups" within this age range, specifically those with prior dengue infection 6.
Mandatory Pre-Vaccination Testing
Laboratory confirmation of previous dengue infection is REQUIRED before vaccination 1. This includes:
- Detection of anti-DENV IgG using a highly specific serodiagnostic test
- Alternative evidence: Laboratory-confirmed dengue infection (PCR, antigen, or documented seroconversion)
This testing requirement is non-negotiable due to the increased risk of severe dengue in seronegative vaccinees 1.
Dosing Schedule
Two doses administered subcutaneously, 3 months apart 5
Geographic Indications
Vaccination is recommended only for children living in dengue-endemic areas, which in the U.S. includes 1:
- Puerto Rico
- American Samoa
- U.S. Virgin Islands
- Federated States of Micronesia
- Republic of Marshall Islands
- Republic of Palau
Absolute Contraindications
- Dengue-naïve status (no prior dengue infection) 1
- Age <9 years or >16 years 1
- Severe allergic reaction to vaccine components
- Immunocompromised states (as with other live-attenuated vaccines)
- Pregnancy (theoretical risk with live-attenuated vaccines)
Critical Clinical Pitfalls
The most dangerous error is vaccinating dengue-naïve individuals, as this creates a "priming" effect that increases risk of severe dengue upon subsequent natural infection 1, 7. This phenomenon was discovered through retrospective analysis of clinical trial data in 2017, leading to major revisions in WHO and ACIP recommendations 7.
Do not rely on patient/parent recall of previous dengue infection alone - laboratory confirmation is mandatory 1.
Special Populations
Travelers
- Dengvaxia is NOT recommended for travelers 3
- For Qdenga (where available outside the U.S.): Swiss and French travel medicine experts recommend vaccination only for travelers ≥6 years with documented prior dengue infection AND expected significant exposure 3, 2
Elderly (≥60 years)
- Limited data on vaccine efficacy in this population 8
- No current ACIP recommendations for this age group
- Emerging evidence suggests this population may benefit given shifting disease burden, but more research needed 8
Algorithm for Clinical Decision-Making
- Verify age: Is patient 9-16 years old? If NO → Do not vaccinate
- Verify residence: Does patient live in dengue-endemic U.S. territory? If NO → Do not vaccinate
- Obtain laboratory testing: Order highly specific anti-DENV IgG test
- Interpret results: Is test positive for prior dengue infection? If NO → Do not vaccinate
- If all criteria met: Administer first dose, schedule second dose 3 months later
The evidence strongly supports a conservative approach prioritizing safety over broad coverage, given the paradoxical increased risk in seronegative individuals that fundamentally distinguishes dengue vaccines from other routine immunizations 1, 7.